grant
Differences in Tumor Biology of Multiple Myeloma
Organization MAYO CLINIC ROCHESTERLocation ROCHESTER, UNITED STATESPosted 19 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025AccountingAffectAfrican ancestryAfrican descentAgeAge of OnsetAntioncogene Protein p53Blood Plasma CellCancersCell LineCellLineCellular Tumor Antigen P53Chromosomal, Gene, or Protein AbnormalityClinicCytogenetic or Molecular Genetic AbnormalityCytometryDNA mutationDataDiseaseDisorderDrugsDysfunctionEuropean ancestryFrequenciesFunctional disorderGeneticGenetic AbnormalityGenetic ChangeGenetic DifferentiationGenetic DivergenceGenetic DiversityGenetic DriftGenetic RiskGenetic VariationGenetic defectGenetic mutationGenomicsGoalsHematopoietic Cell TumorHematopoietic MalignanciesHematopoietic NeoplasmsHematopoietic Neoplasms including LymphomasHematopoietic TumorHematopoietic and Lymphoid Cell NeoplasmHematopoietic and Lymphoid NeoplasmsHumanIncidenceIndividualMalignant Hematopoietic NeoplasmMalignant NeoplasmsMalignant TumorMedicationModern ManMolecular AbnormalityMultiple MyelomaMutationNewly DiagnosedOncoprotein p53OutcomeP53PatientsPersonsPharmaceutical PreparationsPhosphoprotein P53Phosphoprotein pp53PhysiopathologyPlasma CellsPlasma-Cell MyelomaPlasmacytesPopulationProspective StudiesProtein TP53Public HealthRNA SeqRNA sequencingRNAseqRegimenResearchRetrospective StudiesRiskSelection for TreatmentsStrains Cell LinesT-CellsT-LymphocyteTP53TP53 geneTRP53TestingTherapeuticTumor BiologyTumor Protein p53Tumor Protein p53 GeneVariantVariationagesblood cancercancer microenvironmentcancer of bloodcancer of the bloodcohortcultured cell linedrug sensitivitydrug/agentexperiencegenome mutationgenome scalegenome-widegenomewideimprovedmalignancymolecular aberrationsmyelomamyelomatosisneoplasm/cancernovelp53 Antigenp53 Genesp53 Tumor Suppressorpathophysiologypatient populationplasmocytepredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerprognosticationprotein p53responseresponse to therapyresponse to treatmentselection of treatmentstandard of caresurvival outcometherapeutic responsetherapy responsetherapy selectionthymus derived lymphocytetranscriptome sequencingtranscriptomic sequencingtranscriptomicstreatment responsetreatment responsivenesstreatment selectiontumortumor microenvironmentyounger age
Description preview
Multiple myeloma (MM) is the most common blood cancer in persons with a higher proportion of African Ancestry (AA) compared to those with a higher proportion of European Ancestry (EA). It remains unknown why the incidence and outcomes of MM vary by genetic ancestry. Large-scale studies comparing variation of the MM tumor, its tumor…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click